Compass Therapeutics Profitability Analysis
| CMPX Stock | USD 5.17 0.20 3.72% |
Net Loss | First Reported 2019-06-30 | Previous Quarter -19.9 M | Current Value -14.3 M | Quarterly Volatility 9.6 M |
For Compass Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Compass Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Compass Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Compass Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Compass Therapeutics over time as well as its relative position and ranking within its peers.
Check out Trending Equities. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compass Therapeutics. If investors know Compass will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Compass Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Compass Therapeutics is measured differently than its book value, which is the value of Compass that is recorded on the company's balance sheet. Investors also form their own opinion of Compass Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Compass Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compass Therapeutics' market value can be influenced by many factors that don't directly affect Compass Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Compass Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Compass Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compass Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Compass Therapeutics Return On Asset vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Compass Therapeutics's current stock value. Our valuation model uses many indicators to compare Compass Therapeutics value to that of its competitors to determine the firm's financial worth. Compass Therapeutics is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . At this time, Compass Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Compass Therapeutics' earnings, one of the primary drivers of an investment's value.Compass Return On Asset vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Compass Therapeutics |
| = | -0.38 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Compass Therapeutics |
| = | -0.23 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Compass Return On Asset Comparison
Compass Therapeutics is currently under evaluation in return on asset category among its peers.
Compass Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Compass Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Compass Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Compass Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Compass Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 241.5 K | 253.6 K | |
| Net Interest Income | 8.4 M | 8.8 M | |
| Interest Income | 8.4 M | 8.8 M | |
| Operating Income | -51 M | -53.5 M | |
| Net Loss | -44.4 M | -46.7 M | |
| Income Before Tax | -44.4 M | -46.7 M | |
| Total Other Income Expense Net | 8.3 M | 8.8 M | |
| Net Loss | -35.3 M | -37.1 M | |
| Net Loss | -44.4 M | -46.7 M | |
| Income Tax Expense | -2.2 M | -2.1 M | |
| Non Operating Income Net Other | 2.8 M | 2.9 M | |
| Change To Netincome | 6 M | 5.7 M | |
| Net Loss | (0.32) | (0.34) | |
| Income Quality | 0.82 | 0.65 | |
| Net Income Per E B T | 1.15 | 1.10 |
Compass Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Compass Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Compass Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Compass Therapeutics' important profitability drivers and their relationship over time.
Compass Therapeutics Profitability Trends
Compass Therapeutics profitability trend refers to the progression of profit or loss within a business. An upward trend means that Compass Therapeutics' profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Compass Therapeutics' gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.
Compass Therapeutics Profitability Drivers Correlations
One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Compass Therapeutics different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Compass Therapeutics in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Compass Therapeutics' future profitability.
Click cells to compare fundamentals
Compass Therapeutics Earnings Estimation Breakdown
The calculation of Compass Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Compass Therapeutics is estimated to be -0.1014 with the future projection ranging from a low of -0.14 to a high of -0.08. Please be aware that this consensus of annual earnings estimates for Compass Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.14 Lowest | Expected EPS | -0.08 Highest |
Compass Therapeutics Earnings Projection Consensus
Suppose the current estimates of Compass Therapeutics' value are higher than the current market price of the Compass Therapeutics stock. In this case, investors may conclude that Compass Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Compass Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 14 | 71.13% | 0.0 | -0.1014 | -0.45 |
Compass Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Compass Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Compass Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Compass Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Compass Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Compass Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Compass Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Compass Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Compass Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-05 | 2025-09-30 | -0.1432 | -0.08 | 0.0632 | 44 | ||
2025-08-11 | 2025-06-30 | -0.12 | -0.14 | -0.02 | 16 | ||
2025-05-08 | 2025-03-31 | -0.11 | -0.12 | -0.01 | 9 | ||
2025-02-28 | 2024-12-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2024-11-12 | 2024-09-30 | -0.11 | -0.08 | 0.03 | 27 | ||
2024-08-12 | 2024-06-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2024-05-13 | 2024-03-31 | -0.11 | -0.08 | 0.03 | 27 | ||
2024-03-21 | 2023-12-31 | -0.09 | -0.11 | -0.02 | 22 | ||
2023-11-09 | 2023-09-30 | -0.11 | -0.08 | 0.03 | 27 | ||
2023-08-03 | 2023-06-30 | -0.08 | -0.09 | -0.01 | 12 | ||
2023-05-04 | 2023-03-31 | -0.11 | -0.06 | 0.05 | 45 | ||
2023-03-15 | 2022-12-31 | -0.11 | -0.1 | 0.01 | 9 | ||
2022-11-09 | 2022-09-30 | -0.11 | -0.12 | -0.01 | 9 | ||
2022-08-01 | 2022-06-30 | -0.08 | -0.08 | 0.0 | 0 | ||
2022-05-09 | 2022-03-31 | -0.11 | -0.07 | 0.04 | 36 | ||
2022-03-18 | 2021-12-31 | -0.07 | -0.21 | -0.14 | 200 | ||
2021-11-12 | 2021-09-30 | -0.12 | -0.1 | 0.02 | 16 | ||
2021-08-16 | 2021-06-30 | -1.03 | -1.07 | -0.04 | 3 |
Use Compass Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compass Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compass Therapeutics will appreciate offsetting losses from the drop in the long position's value.Compass Therapeutics Pair Trading
Compass Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Compass Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compass Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compass Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compass Therapeutics to buy it.
The correlation of Compass Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compass Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compass Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compass Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Compass Therapeutics position
In addition to having Compass Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.